Pfizer Inc
PFE25.470USD
+0.180+0.71%
Fechamento 01/09, 16:00（ET）Cotações atrasadas em 15 min
144.82BValor de mercado
14.72P/L TTM
Mais detalhes de Pfizer Inc Empresa
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Informações de Pfizer Inc
Código da empresaPFE
Nome da EmpresaPfizer Inc
Data de listagemFeb 22, 2080
CEOBourla (Albert)
Número de funcionários81000
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 22
Endereço66 Hudson Boulevard East
CidadeNEW YORK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal10001-2192
Telefone12127332323
Sitehttps://www.pfizer.com/
Código da empresaPFE
Data de listagemFeb 22, 2080
CEOBourla (Albert)
Executivos da empresa Pfizer Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+29174.00%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+1543.00%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
Outro
8.93B
53.62%
Por RegiãoUSD
Nome
Receita
Proporção
United States
10.69B
64.19%
Developed Markets
3.70B
22.19%
Emerging Markets
2.27B
13.61%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
Outro
8.93B
53.62%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
Outro
76.30%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
Outro
76.30%
Tipos de investidores
Investidores
Proporção
Investment Advisor
33.34%
Investment Advisor/Hedge Fund
23.13%
Research Firm
2.99%
Pension Fund
2.47%
Bank and Trust
1.76%
Sovereign Wealth Fund
1.72%
Insurance Company
1.27%
Hedge Fund
0.93%
Holding Company
0.05%
Outro
32.35%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
4669
3.85B
67.65%
-88.11M
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
531.51M
9.35%
+833.15K
+0.16%
Sep 30, 2025
State Street Investment Management (US)
299.09M
5.26%
+2.79M
+0.94%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
294.15M
5.17%
+5.26M
+1.82%
Sep 30, 2025
Geode Capital Management, L.L.C.
129.01M
2.27%
+1.54M
+1.20%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
60.46M
1.06%
-16.54M
-21.48%
Sep 30, 2025
State Farm Insurance Companies
57.66M
1.01%
+71.50K
+0.12%
Sep 30, 2025
MFS Investment Management
54.96M
0.97%
-17.80M
-24.46%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
52.35M
0.92%
-2.30M
-4.21%
Sep 30, 2025
BlackRock Investment Management (UK) Ltd.
50.76M
0.89%
+1.88M
+3.85%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: seg, 1 de dez
Atualizado em: seg, 1 de dez
Nome
Proporção
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
Ver Mais
VanEck Pharmaceutical ETF
Proporção10.43%
First Trust NASDAQ Pharmaceuticals ETF
Proporção7.73%
Franklin US Dividend Booster Index ETF
Proporção7.39%
First Trust Morningstar Dividend Leaders Index Fund
Proporção6.54%
WBI Power Factor High Dividend ETF
Proporção4.87%
Invesco Pharmaceuticals ETF
Proporção4.84%
Coastal Compass 100 ETF
Proporção4.8%
iShares U.S. Pharmaceuticals ETF
Proporção4.43%
Amplify Weight Loss Drug & Treatment ETF
Proporção4.14%
Roundhill GLP-1 & Weight Loss ETF
Proporção3.73%
Dividendo
Um total de
36.47B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Dec 12, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026
Jan 23, 2026
Mar 06, 2026
Jan 23, 2026
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de Pfizer Inc?
Os cinco principais acionistas de Pfizer Inc são:
The Vanguard Group, Inc. detém 531.51M Ações, representando 9.35% do total de Ações.
State Street Investment Management (US) detém 299.09M Ações, representando 5.26% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 294.15M Ações, representando 5.17% do total de Ações.
Geode Capital Management, L.L.C. detém 129.01M Ações, representando 2.27% do total de Ações.
Norges Bank Investment Management (NBIM) detém 93.65M Ações, representando 1.65% do total de Ações.
The Vanguard Group, Inc. detém 531.51M Ações, representando 9.35% do total de Ações.
State Street Investment Management (US) detém 299.09M Ações, representando 5.26% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 294.15M Ações, representando 5.17% do total de Ações.
Geode Capital Management, L.L.C. detém 129.01M Ações, representando 2.27% do total de Ações.
Norges Bank Investment Management (NBIM) detém 93.65M Ações, representando 1.65% do total de Ações.
Quais são os três principais tipos de acionistas de Pfizer Inc?
Os três principais tipos de acionistas da Pfizer Inc são:
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
Quantas instituições possuem ações da Pfizer Inc (PFE)?
Em 2025Q4, 4669 instituições possuíam ações da Pfizer Inc, com valor de mercado aproximado de 3.85B, representando 67.65% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em 0.81%.
Qual é a maior fonte de receita da Pfizer Inc?
Em FY2025Q3, o segmento de negócios Eliquis alliance revenues and direct sales gerou a maior receita para Pfizer Inc, totalizando 2.02B e representando 12.10% da receita total.
